Quick Answer
NEKTAR THERAPEUTICS reported Stockholders Equity of $89.83 million for the year ending 2025.
- NEKTAR THERAPEUTICS showed an increase of +47.9% in Stockholders Equity from 2024 to 2025.
- This data is from NEKTAR THERAPEUTICS's annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$9.81 million | Q2 2014: -$35.36 million | Q3 2014: $47.22 million | Q1 2015: $77.31 million | Q2 2015: $35.10 million | Q3 2015: $39.05 million | Q1 2016: -$275.0 thousand | Q2 2016: -$39.25 million | Q3 2016: -$67.85 million | Q1 2017: $44.75 million | Q2 2017: $3.39 million | Q3 2017: $84.16 million | Q1 2018: $58.28 million | Q2 2018: $1.86 billion | Q3 2018: $1.79 billion | Q1 2019: $1.63 billion | Q2 2019: $1.56 billion | Q3 2019: $1.49 billion | Q1 2020: $1.30 billion | Q2 2020: $1.26 billion | Q3 2020: $1.17 billion | Q1 2021: $994.51 million | Q2 2021: $904.98 million | Q3 2021: $801.54 million | Q1 2022: $607.89 million | Q2 2022: $458.73 million | Q3 2022: $412.22 million | Q1 2023: $240.87 million | Q2 2023: $196.96 million | Q3 2023: $159.37 million | Q1 2024: $126.71 million | Q2 2024: $79.69 million | Q3 2024: $48.88 million | Q1 2025: $13.74 million | Q2 2025: -$24.21 million | Q3 2025: $85.09 million.
- Over the full 15 years of available data (2011 to 2025), NEKTAR THERAPEUTICS's Stockholders Equity has declined by 54.6%.
- Historical annual values: Fiscal year 2025: $89.83 million | Fiscal year 2024: $60.74 million | Fiscal year 2023: $130.99 million | Fiscal year 2022: $366.64 million | Fiscal year 2021: $679.51 million | Fiscal year 2020: $1.08 billion | Fiscal year 2019: $1.41 billion | Fiscal year 2018: $1.72 billion | Fiscal year 2017: $87.83 million | Fiscal year 2016: $88.13 million | Fiscal year 2015: $6.43 million | Fiscal year 2014: $36.33 million | Fiscal year 2013: -$89.90 million | Fiscal year 2012: $47.02 million | Fiscal year 2011: $197.81 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: